NASDAQ : DRTS
Alpha Tau Medical Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 13.06 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.21B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.21B |
| Enterprise Value | 1.12B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 92.33M |
| Shares Outstanding | 92.33M |
| Shares Change (YoY) | +20.98% |
| Shares Change (QoQ) | +1.39% |
| Owned by Insiders (%) | 14.91% |
| Owned by Institutions (%) | 9.04% |
| Float | 64.10M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 333.17 |
| PB Ratio | 27.37 |
| P/TBV Ratio | 27.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.09 |
| Quick Ratio | 10.45 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -140.08 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -141.68% |
| Return on Assets (ROA) | -25.71% |
| Return on Invested Capital (ROIC) | -39.61% |
| Return on Capital Employed (ROCE) | -40.47% |
| Weighted Average Cost of Capital (WACC) | 11.21% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$765,074 |
| Employee Count | 121 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 175,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.29 |
| 52-Week Price Change | +219.32% |
| 50-Day Moving Average | 14.26 |
| 200-Day Moving Average | 10.60 |
| Relative Strength Index (RSI) | 43.27 |
| Average Volume (20 Days) | 473,278 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.44M |
| Short Previous Month | 3.45M |
| Short % of Shares Out | 3.72% |
| Short % of Float | 5.36% |
| Short Ratio (days to cover) | 7.22 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -50.43M |
| Pretax Income | -92.40M |
| Net Income | -92.57M |
| EBITDA | -48.76M |
| EBIT | -50.43M |
| Earnings Per Share (EPS) | -$1.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 100.64M |
| Total Debt | 15.15M |
| Net Cash | 85.49M |
| Net Cash Per Share | $0.93 |
| Equity (Book Value) | 44.06M |
| Book Value Per Share | 0.48 |
| Working Capital | 97.20M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.81M |
| Capital Expenditures | -3.30M |
| Depreciation & Amortization | 1.67M |
| Net Borrowing | n/a |
| Free Cash Flow | -16.11M |
| FCF Per Share | -$0.17 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -20.98% |
| Shareholder Yield | n/a |
| Earnings Yield | -8.05% |
| FCF Yield | -1.34% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.80 |
| Price Target Difference | 36.29% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |